The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the revocation of the marketing authorization for Tavneos (avacopan), an Amgen-manufactured treatment for severe active granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA). The recommendation follows a review of clinical data that regulators determined failed to confirm the drug’s long-term benefit-risk balance.
Why did the EMA recommend revoking Tavneos?
The CHMP’s recommendation, issued in late 2024, centers on the results of the ADVOCATE phase 3 clinical trial. While the study initially supported the drug’s approval for patients with ANCA-associated vasculitis, subsequent regulatory scrutiny identified issues regarding the robustness of the data.
According to the European Medicines Agency, the committee concluded that the evidence provided by the manufacturer did not sufficiently demonstrate that the therapeutic benefits of the drug outweighed its potential risks. The agency noted that the data did not provide enough evidence to maintain the authorization under the current terms. This decision marks a significant regulatory setback for Amgen, which acquired the drug through its $3.7 billion purchase of ChemoCentryx in 2022.
What is the clinical context for the decision?
Tavneos is a first-in-class C5a receptor antagonist designed to treat two forms of ANCA-associated vasculitis: GPA and MPA. These are rare, life-threatening autoimmune diseases that cause inflammation of the small blood vessels, often leading to kidney failure.
The drug was intended to act as an alternative to high-dose glucocorticoids, which are standard-of-care treatments that often carry severe long-term side effects. However, the CHMP’s assessment highlighted that the clinical study design failed to provide the necessary long-term clarity required for continued authorization in the European Union market.
How does this affect Amgen’s market position?
The revocation recommendation impacts Amgen’s rare-disease portfolio strategy. When Amgen acquired ChemoCentryx, the primary value driver was the potential for Tavneos to capture significant market share from traditional steroid treatments.
| Feature | Details |
|---|---|
| Drug Name | Tavneos (avacopan) |
| Indication | Severe active GPA and MPA |
| Regulatory Status | CHMP recommendation to revoke authorization |
| Primary Owner | Amgen |
While the EMA recommendation is a major hurdle, it does not automatically pull the drug from the market. The procedure now moves to the European Commission, which typically follows the CHMP’s scientific opinion to issue a final, legally binding decision. Amgen has the right to request a re-examination of the CHMP opinion within 15 days of receiving the notification.
What happens next for patients and providers?
Patients currently prescribed Tavneos are advised to consult their healthcare providers regarding their treatment plans. Because the process is ongoing, the drug remains available in the EU until the European Commission issues a final ruling.
The regulatory scrutiny in Europe stands in contrast to the status of the drug elsewhere. In the United States, the Food and Drug Administration (FDA) approved Tavneos in 2021 for the treatment of adult patients with severe active ANCA-associated vasculitis. As of late 2024, the FDA has not issued similar actions regarding the drug’s authorization in the U.S. market. Investors and clinicians will be monitoring the European Commission’s final determination, which will clarify whether the drug can remain on the market in member states or if a formal withdrawal process will begin.